Playa-Albinyana, Heribert http://orcid.org/0000-0002-3447-3848
Arenas, Fabian
Royo, Romina
Giró, Ariadna
López-Oreja, Irene http://orcid.org/0000-0001-6756-1820
Aymerich, Marta
López-Guerra, Mònica
Frigola, Gerard http://orcid.org/0000-0001-6794-6456
Beà, Sílvia
Delgado, Julio http://orcid.org/0000-0002-5157-4376
Garcia-Roves, Pablo M.
Campo, Elías http://orcid.org/0000-0001-9850-9793
Nadeu, Ferran http://orcid.org/0000-0003-2910-9440
Colomer, Dolors http://orcid.org/0000-0001-7486-8484
Article History
Received: 13 June 2023
Revised: 8 November 2023
Accepted: 15 November 2023
First Online: 28 November 2023
Competing interests
: E.C. has been a consultant for Takeda, NanoString, AbbVie and Illumina; has received honoraria from Janssen, EUSPharma and Roche for speaking at educational activities and research funding from AstraZeneca and is an inventor on 2 patents filed by the National Institutes of Health, National Cancer Institute: “Methods for selecting and treating lymphoma types,” licensed to NanoString Technologies, and “Evaluation of mantle cell lymphoma and methods related thereof”, not related to this project. F.N. has received honoraria from Janssen, AbbVie, AstraZeneca and Sophia Genetics for speaking at educational activities. D.C. has received honoraria from AbbVie, Sophia Genetics, Thermofisher and AstraZeneca for speaking at educational activities. The remaining authors declare no competing financial interests.